Tactile Systems Technology Inc

Tactile Systems Technology Inc(TCMD)股票分析

$23.280

-0.237 (-1.02%)收盘时

Loading chart…
最高
23.860
开盘
23.340
成交量加权均价
23.42
成交量
148.92K
市值
274.93M
最低
23.120
成交额
3.49M
企业价值/息税折旧摊销前利润(TTM)
12.46

Tactile Systems Technology, Inc., doing business as Tactile Medical, is a medical technology company that manufactures and distributes medical devices for the treatment of patients with chronic diseases at home. The Company's areas of therapeutic focus are vascular disease, oncology and providing airway clearance therapy for those suffering from chronic respiratory conditions. It is developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease. It markets Flexitouch Plus and Entre Plus systems as at-home therapies for the treatment of lymphedema and chronic venous insufficiency. It markets AffloVest as an at-home therapy intended to promote airway clearance. Its Flexitouch Plus system is a fully automated, programmable, advanced pneumatic compression device. It also offers Kylee, a free mobile application that helps patients learn about lymphedema.

AI 分析 of Tactile Systems Technology Inc (TCMD)

买入

Tactile Systems Technology Inc is a good buy right now due to its current price of $22.52, which is significantly lower than the analyst price target of $36, indicating a potential upside of 60%. Additionally, the company has shown strong revenue growth with Q2 2026 revenue at $85.7 million, a 9% year-over-year increase, and a gross margin of 76.3%. The main risk is the recent decline in stock price, with a 1-year change of +54.14% and a year-to-date change of -17.81%, indicating volatility.

分析师评级(6)

上行空间 +36.04%
买入
6 买入
0 持有
0 卖出
当前: 23.28
最低
28.00
平均
31.67
最高
35.00

BTIG

2026-10-12

目标价

$35

买入

B. Riley

2026-05-07

目标价

$36

买入

BTIG

2026-05-05

目标价

$40

买入

BTIG

2026-02-18

目标价

$38

买入

B. Riley

2026-02-18

目标价

$32

中性

估值指标

Tactile Systems Technology Inc(TCMD)当前预期市盈率为 19.12,5 年平均预期市盈率为 79.55。

预期市盈率

合理
5 年均值 P/E
79.55
当前P/E
19.12
高估
450.83
低估
-291.72

预期 EV/EBITDA

合理
5 年均值 EV/EBITDA
-7.55
当前EV/EBITDA
12.46
高估
75.70
低估
-90.81

预期市销率

合理
5 年均值 P/S
1.22
当前P/S
1.34
高估
1.64
低估
0.81

Alphio AI 对 TCMD 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%TCMD

$12.55

情景价格

基

基准

基准 · 50%TCMD

$12.06

情景价格

悲

悲观

悲观 · 25%TCMD

$10.94

情景价格

持有 TCMD 的大户

F

First Light Asset Management, LLC

+ 持有TCMD

-8.27%

3个月收益率

事件时间线

2026-08-10 (ET)

16:30:00

Tactile Medical Q2 Revenue $85.7M Beats Expectations

2026-05-04 (ET)

16:30:00

Tactile Medical Q1 Revenue $75.27M, Exceeds Expectations

16:30:00

Company Updates 2026 Revenue Outlook to $368 Million

2026-03-09 (ET)

08:30:00

Tactile Systems Appoints Andrea Pearson to Board of Directors

2026-02-17 (ET)

17:00:00

Tactile Systems Acquires LymphaTech for $6.8M

资讯

TCMD 常见问题 —— 由 Alphio AI 解答

Tactile Systems Technology, Inc., doing business as Tactile Medical, is a medical technology company that manufactures and distributes medical devices for the treatment of patients with chronic diseases at home. The Company's areas of therapeutic focus are vascular disease, oncology and providing airway clearance therapy for those suffering from chronic respiratory conditions. It is developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease. It markets Flexitouch Plus and Entre Plus systems as at-home therapies for the treatment of lymphedema and chronic venous insufficiency. It markets AffloVest as an at-home therapy intended to promote airway clearance. Its Flexitouch Plus system is a fully automated, programmable, advanced pneumatic compression device. It also offers Kylee, a free mobile application that helps patients learn about lymphedema. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Tactile Systems Technology Inc is a good buy right now due to its current price of $22.52, which is significantly lower than the analyst price target of $36, indicating a potential upside of 60%. Additionally, the company has shown strong revenue growth with Q2 2026 revenue at $85.7 million, a 9% year-over-year increase, and a gross margin of 76.3%. The main risk is the recent decline in stock price, with a 1-year change of +54.14% and a year-to-date change of -17.81%, indicating volatility.

6 analysts cover TCMD: 6 rate it Buy, 0 Hold and 0 Sell. The average price target is 31.67.

暂无帖子

注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易